Vivos Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vivos Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Vivos Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 559 %, a 239% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 559 +394 +239% Jun 30, 2024
Q1 2024 1.38K +1.28K +1259% Mar 31, 2024
Q4 2023 443 +373 +530% Dec 31, 2023
Q3 2023 294 +245 +502% Sep 30, 2023
Q2 2023 165 +128 +346% Jun 30, 2023
Q1 2023 102 +71.5 +237% Mar 31, 2023
Q4 2022 70.3 +39.1 +125% Dec 31, 2022
Q3 2022 48.8 +14.6 +42.6% Sep 30, 2022
Q2 2022 37 Jun 30, 2022
Q1 2022 30.2 Mar 31, 2022
Q4 2021 31.2 Dec 31, 2021
Q3 2021 34.2 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.